ACTOS (PIOGLITAZONE): NEW THERAPY FOR TYPE 2 DIABETES WITH NOVEL MODE OF ACTION LAUNCHED IN UKNovember 07, 2000“Type 2 diabetes is characterised by high blood sugar but also by lipid abnormalities, particularly raised triglycerides and low HDL (so-called good) cholesterol. This spectrum of metabolic imbalance related to insulin resistance together with raised blood pressure is the characteristic signature of most people with Type 2 diabetes. Any compound with the ability to improve this metabolic spectrum has great potential to improve the treatment of Type 2 diabetes” according to Professor John Betteridge, Professor of Endocrinology and Metabolism at University College, London. Professor Betteridge added “Pioglitazone, from available scientific evidence, reduces insulin resistance helping to address these metabolic concerns”. Takeda UK Limited today announced that ACTOS® (pioglitazone) is now available in the UK for the treatment of Type 2 diabetes mellitus. ACTOS is approved for use in the oral combination treatment of Type 2 diabetes mellitus in patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin (in obese patients) or a sulphonylurea (in patients for whom metformin is not tolerated or contraindicated). ACTOS® is taken once daily and is available in 15 and 30 milligram tablets. Dr David Kerr, Consultant Physician, Bournemouth Diabetes & Endocrinology Centre, The Royal Bournemouth Hospital said “The availability of pioglitazone is good news for both patients and doctors. By improving insulin sensitivity, pioglitazone in combination with metformin and a sulphonylurea significantly reduces blood glucose levels which is vital when trying to manage Type 2 diabetes. In addition, pioglitazone in combination therapy decreased triglycerides and increased high density lipoprotein cholesterol (HDL-C) with no significant effect on low density lipoprotein cholesterol (LDL-C) compared to placebo.” It is estimated that 1.4 million people in the UK have diabetes.1 Of these, between 75% and 90% have Type 2 diabetes.1 Dr Roger Gadsby a General Practitioner in Warwick commented that “The treatment of Type 2 diabetes is largely a condition managed in primary care. Any therapy, such as pioglitazone, that is taken once a day and is easy to use will be a valuable addition to the physician’s armamentarium. I believe that pioglitazone has these characteristics.”
Note to Editors: Type 2 diabetes As Type 2 diabetes progresses, the heart, the circulation, the eyes and the kidneys can all be affected and severe complications can arise which may cause severe disability and restrict a patient’s mobility and ability to work. The cost of treating Type 2 diabetes and its associated complications is projected to total £4.8 billion in 2000. This accounts for approximately 9% of total NHS resources.1 ACTOS® Takeda Takeda is committed to the research and development of novel drug therapies. Takeda has been investing in research into diabetes for over 30 years and were the originators of the thiazolidinedione class of drugs and the company is constantly striving to contribute to the treatment of Type 2 diabetes. Takeda UK Ltd. is a wholly owned subsidiary of Takeda Chemical Industries, Ltd.
Date of Preparation: October 2000
| |||||||||||||||||||||
|
Related Diabetes News Articles Class of diabetes drugs carries significant cardiovascular risks A class of oral drugs used to treat type 2 diabetes may make heart failure worse, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members. Not all fat is created equal A Temple University study finds fat in obese patients is "sick" when compared to fat in lean patients. Young Type-2 Diabetic Men Suffer Low Testosterone Levels, Study Shows Young men with type 2 diabetes have significantly low levels of testosterone, endocrinologists at the University at Buffalo have found -- a condition that could have a critical effect on their quality of life and on their ability to father children. Early trigger for type-1 diabetes found in mice, Stanford scientists report Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins. Findings challenge common practice regarding glucose control for critically ill patients An analysis of randomized trials indicates that for critically ill adults, tight glucose control is not associated with a significantly reduced risk of death in the hospital, but is associated with an increased risk of hypoglycemia, calling into question the recommendation by many professional societies for tight glucose control for these patients. Chronic stress alters our genetic immune response Most people would agree that stress increases your risk for illness and this is particularly true for severe long-term stresses, such as caring for a family member with a chronic medical illness. Low cholesterol associated with cancer in diabetics Low levels of LDL cholesterol as well as high levels are associated with cancer in patients with type 2 diabetes. Potential diabetes treatment selectively kills autoimmune cells from human patients In experiments using blood cells from human patients with diabetes and other autoimmune disorders, Massachusetts General Hospital (MGH) researchers have confirmed the mechanism behind a potential new therapy for type 1 diabetes. Scientists discover leptin can also aid type 1 diabetics Terminally ill rodents with type 1 diabetes have been restored to full health with a single injection of a substance other than insulin by scientists at UT Southwestern Medical Center. Nano-sized 'trojan horse' to aid nutrition Researchers from Monash University have designed a nano-sized "trojan horse" particle to ensure healing antioxidants can be better absorbed by the human body. More Diabetes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||